Literature DB >> 12083371

Elongation factor 2 as a target for selective inhibition of protein synthesis in vitro by the novel aromatic bisamidine.

Anna Gajko-Galicka1, Krzysztof Bielawski, Krystyna Sredzinska, Anna Bielawska, Andrzej Gindzienski.   

Abstract

The effect of the novel aromatic bisamidine 1 on protein synthesis in cell-free translational system isolated from rat livers was studied. The bisamidine 1 caused inhibition of [14C]leucine incorporation into proteins proportionally to its concentration. To establish a precise mechanism of inhibition, we evaluated the effect of the bisamidine 1 on the isolated ribosomes and purified to homogeneity elongation factors. Preincubation of the bisamidine 1 with ribosomes resulted in partial inhibition of their activity in whole elongation system. The eucaryotic elongation factor 1 (eEF-1) was not significantly affected by the bisamidine 1. In contrast to eEF-1, the bisamidine 1 preincubated with the eucaryotic elongation factor 2 (eEF-2) caused total inhibition of its activity in the translocation process. The inhibitory effect of the bisamidine 1 on eEF-2 activity was confirmed in diphtheria toxin-dependent ADP-ribosylation reaction. The results suggest a high action specificity of the bisamidine 1 as potential anticancer drug, since the primary target seems to be highly conserved protein-elongation factor 2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12083371     DOI: 10.1023/a:1015548131930

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

Review 1.  Eukaryotic protein elongation factors.

Authors:  B Riis; S I Rattan; B F Clark; W C Merrick
Journal:  Trends Biochem Sci       Date:  1990-11       Impact factor: 13.807

2.  Possibility of the transformation of eEF-2 (100 kDa) to eEF-2 (65 kDa) in the peptide elongation process in vitro.

Authors:  A Gajko; K Sredzińska; W Galasiński; A Gindzieński
Journal:  Biochem Biophys Res Commun       Date:  1999-02-16       Impact factor: 3.575

Review 3.  Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues.

Authors:  C Bailly; J B Chaires
Journal:  Bioconjug Chem       Date:  1998 Sep-Oct       Impact factor: 4.774

4.  Estimating the amounts of ADP-ribosylatable active elongation factor-2 in mammalian cell-free extracts.

Authors:  B Riis; S I Rattan; B F Clark
Journal:  J Biochem Biophys Methods       Date:  1989-10

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Multiformity of elongation factor eEF-2 isolated from rat liver cells.

Authors:  A Gajko; W Gałasiński; A Gindzieński
Journal:  Biochem Biophys Res Commun       Date:  1994-07-29       Impact factor: 3.575

7.  Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.

Authors:  C Bailly; L Dassonneville; C Carrasco; D Lucas; A Kumar; D W Boykin; W D Wilson
Journal:  Anticancer Drug Des       Date:  1999-02

8.  Inhibitory effects of pentamidine analogues on protein biosynthesis in vitro.

Authors:  K Bielawski; A Galicka; A Bielawska; K Sredzińska
Journal:  Acta Biochim Pol       Date:  2000       Impact factor: 2.149

9.  Localization of the sites of ADP-ribosylation and GTP binding in the eukaryotic elongation factor EF-2.

Authors:  L Nilsson; O Nygård
Journal:  Eur J Biochem       Date:  1985-04-15

10.  Purification and characterization of the protein kinase eEF-2 isolated from rat liver cells.

Authors:  A Gajko; W Gałasiński; A Gindzieński
Journal:  Acta Biochim Pol       Date:  1994       Impact factor: 2.149

View more
  1 in total

1.  An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.

Authors:  Geetika Sethi; Harsh B Pathak; Hong Zhang; Yan Zhou; Margret B Einarson; Vinod Vathipadiekal; Sumedha Gunewardena; Michael J Birrer; Andrew K Godwin
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.